An observational study in Bronchopulmonary Dysplasia, sponsored by Fondazione IRCCS San Gerardo dei Tintori. Recruiting at 6 sites in 5 countries. Open to participants aged 5 Days to 9 Days. Per ClinicalTrials.gov, last updated 2024-03-06.
Sponsored by Fondazione IRCCS San Gerardo dei Tintori · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Bronchopulmonary Dysplasia with a site in Italy — 6 open to participants now, 8 under way, 1 of them phase 3. Bronchopulmonary Dysplasia · Italy.
Among the 16 studies in Bronchopulmonary Dysplasia with a site in Italy, this one is one of 3 that started in 2023, is one of 4 observational ones, and was the 12th registered.
363 studies on the registry are indexed under Bronchopulmonary Dysplasia; 85 are open to participants now.
Browse Bronchopulmonary Dysplasia studies →6 of the 16 studies in Bronchopulmonary Dysplasia with a site in Italy are open now. Recruiting first, the newest first:
Airway Therapeutics, Inc. · Sites in Italy, Argentina, Belgium and 7 more countries
Ages 0 min–96 hrs
Azienda USL Reggio Emilia - IRCCS · Sites in Italy
Ages up to 31 wk
EXO Biologics S.A. · Sites in Italy, Belgium
Ages up to 10 days
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 24 wk–27 wk
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 1 hrs–24 hrs
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 57 Bronchopulmonary Dysplasia studies recruiting now, 6 (11%) set no upper age limit and 50 (88%) stop at 75 or younger; 55 take children under 18; 11 take healthy volunteers.
This study: 5 Days to 9 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 3
First in 2008; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is close to the median of 150 across 100 observational studies indexed under Bronchopulmonary Dysplasia.
Median enrollment 193 across the 12 interventional studies, 35 across the 4 observational. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 16 have an industry lead sponsor. The 10 most frequent:
Fondazione IRCCS San Gerardo dei Tintori is the lead sponsor of 11 studies on the registry; 9 are open to participants now.
Fondazione IRCCS San Gerardo dei Tintori has 1 study filed under Bronchopulmonary Dysplasia — fewer than ten, so there is no comparison to draw.
3 of the studies in Bronchopulmonary Dysplasia with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04372953Murdoch Childrens Research InstitutePositive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The POLAR Trial). | 2026-11-30 |
| NCT06279741EXO Biologics S.A.Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants | 2027-01-31 |
| NCT07633184Azienda USL Reggio Emilia - IRCCSLung Ultrasound Score for Early Prediction of Bronchopulmonary Dysplasia in Preterm Newborns | 2027-02 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Bronchopulmonary Dysplasia with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn about the correlation between respiratory system reactance, as assessed by respiratory oscillometry, and respiratory outcomes in preterm infants born before 32 weeks of gestation. The main question it aims to answer is if the reactance z-score at 7 postnatal days adds to relevant clinical factors in the prediction of bronchopulmonary dysplasia. Participants will receive respiratory oscillometry measurements at 7 ± 2 postnatal days.
Infants will be recruited from those admitted to tertiary-level neonatal intensive care units.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Group of patients who do not receive the diagnosis of bronchopulmonary dysplasia defined as the need for respiratory support at 36 weeks post-mentrual age
Diagnostic Test: Respiratory Oscillometry
Group of patients developing bronchopulmonary dysplasia defined as the need for respiratory support at 36 weeks post-menstrual age.
Diagnostic Test: Respiratory Oscillometry
Measurement of respiratory system reactance by respiratory oscillometry
Respiratory system reactance (Xrs) at the clinical positive end-expiratory pressure
Xrs will be expressed in z-score using reference equation for very preterm infants
Time frame: Xrs will be measured at 7 days of life
Respiratory system reactance (Xrs) at the clinical positive end-expiratory pressure and ± 2 cmH2O
Xrs will be expressed in cmH2O\*S/L
Time frame: Xrs will be measured at 7 days of life
Respiratory support mode
Respiratory support mode will be coded as 0 = no respiratory support, 1 = nasal high flow therapy, 2 = nasal CPAP or nasal IPPV, 3 = invasive mechanical ventilation
Time frame: 7 postnatal days
Fraction of inspired oxygen
Time frame: 7 days of life
Plan to share: No
Started Jul 2023 (actual). Primary completion is estimated for Sep 2024, 13 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione IRCCS San Gerardo dei Tintori